MK-8504
Total Payments
$132,797
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $132,797 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $132,797 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-label, Two Part Study to Evaluate the Pharmacokinetics of Two Formulations of MK-8504 and the Effect of MK-8504 on the Pharmacokinetics of Midazolam in Healthy Adult Subjects | Merck Sharp & Dohme Corporation | $132,797 | 0 |
Top Doctors Receiving Payments for MK-8504
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | — | $132,797 | 6 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $132,797
Product Information
- Type Drug
- Total Payments $132,797
- Total Doctors 0
- Transactions 6
About MK-8504
MK-8504 is a drug associated with $132,797 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2018. In 2018, $132,797 was paid across 6 transactions to 0 doctors.
The most common payment nature for MK-8504 is "Unspecified" ($132,797, 100.0% of total).
MK-8504 is associated with 1 research study, including "An Open-label, Two Part Study to Evaluate the Pharmacokinetics of Two Formulations of MK-8504 and the Effect of MK-8504 on the Pharmacokinetics of Midazolam in Healthy Adult Subjects" ($132,797).